Valuation: argenx SE

Market Cap 56.37B 50.48B 46.43B 42.07B 78.65B 5,352B 80.12B 554B 222B 2,815B 212B 207B 8,878B P/E 2026 *
30.1x
P/E 2027 * 26.3x
Enterprise Value 52.54B 47.06B 43.29B 39.22B 73.31B 4,989B 74.68B 516B 207B 2,624B 197B 193B 8,276B EV / Sales 2026 *
8.25x
EV / Sales 2027 * 6.49x
Free-Float
99.99%
Yield 2026 *
0.04%
Yield 2027 * 0.09%
1 day+0.35%
1 week+3.04%
Current month-4.68%
1 month-4.86%
3 months+4.07%
6 months+23.05%
Current year+12.61%
1 week 771.2
Extreme 771.2
820.6
1 month 682
Extreme 682
862.4
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 12.5
Extreme 12.5
925
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2026
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman 54 06/05/2026
Director/Board Member 76 13/05/2015
Director/Board Member 65 28/04/2016
Date Insider Type Main position Quantity % Market Cap. Importance
23/11/25 Sell

Chief Executive Officer

2,000 0.0032%
23/11/25 Sell

Director

4,680 0.0076%
23/11/25 Exercice

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%+3.04%+12.64%+83.62% 56.16B
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.53%+2.55%+13.90%+104.77% 54.16B
-2.81%-3.95%+22.72%+48.57% 45.33B
-0.33%-3.12%+17.62%+117.27% 42.25B
+0.55%+1.93%+229.73%+928.00% 40.78B
+3.27%+47.40%+110.44%+94.92% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
-1.08%-1.67%-14.69%-3.32% 22.39B
Average -0.03%+4.19%+46.12%+147.40% 41.51B
Weighted average by Cap. -0.05%+3.41%+46.11%+153.53%

Financials

2026 *2027 *
Net sales 6.37B 5.71B 5.25B 4.76B 8.89B 605B 9.06B 62.6B 25.13B 318B 23.91B 23.4B 1,004B 7.77B 6.96B 6.4B 5.8B 10.85B 738B 11.05B 76.38B 30.66B 388B 29.18B 28.56B 1,225B
Net income 1.83B 1.64B 1.5B 1.36B 2.55B 173B 2.6B 17.94B 7.2B 91.19B 6.85B 6.71B 288B 2.11B 1.89B 1.74B 1.58B 2.95B 201B 3B 20.75B 8.33B 106B 7.93B 7.76B 333B
Net Debt -3.82B -3.42B -3.15B -2.85B -5.33B -363B -5.43B -37.55B -15.07B -191B -14.34B -14.04B -602B -5.91B -5.29B -4.87B -4.41B -8.24B -561B -8.4B -58.04B -23.3B -295B -22.17B -21.7B -931B
Projected Income Statement - Annual - argenx SE
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
30/10/26 €807.20 +0.35% 94,245
29/10/26 €804.40 +0.98% 62,464
28/10/26 €796.60 +1.76% 67,787
27/10/26 €782.80 +0.33% 60,326
26/10/26 €780.20 -0.26% 65,204
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - argenx SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
901.30USD
Average target price
1,121.73USD
Spread / Average Target
+24.46%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - argenx SE
  1. Stock Market
  2. Stocks
  3. ARGX Stock